Jump to content
Sclero Forums

Search the Community

Showing results for tags 'prognosis'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 12 results

  1. Increased expression of GAB1 promotes inflammation and fibrosis in systemic sclerosis (SSc). This data suggests that GAB1 has a relatively high expression rate in SSc, and knockdown of GAB1 may attenuate SSc by stimulating inflammatory and fibrotic processes. PubMed, Exp Dermatol, 09/10/2019. (Also see Prognosis and Mortality and Skin Fibrosis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis (dSSc): a European Scleroderma Trials and Research (EUSTAR) analysis. The use of the predictive factors presented here could enable cohort enrichment with patients at risk for overall disease worsening in SSc clinical trials. PubMed, Ann rheumatologist Dis, 06/21/2019. (Also see Diffuse Scleroderma) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. Prediction of progression of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc): the SPAR model. The evidence–based SPAR prediction model developed in our study might be helpful for the risk stratification of patients with mild SSc–ILD in clinical practice and cohort enrichment for future clinical trial design. PubMed, Ann rheumatologist Dis, 06/06/2018. (Also see Severity and Prognosis for Scleroderma Pulmonary Involvement) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  4. First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study. The mode of onset should be considered an independent prognostic factor in systemic sclerosis and, in particular, patients who initially present with non–Raynaud's phenomenon may be considered of poor prognosis. PubMed, Clin Rheumatol, 12/07/2017. (Also see Prognosis and Mortality) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  5. Potential biomarkers in patients with systemic sclerosis (SSc). Endostatin, elastase and the soluble adhesion molecules (sICAM-1 and sVCAM-1) are potentially involved in the pathogenesis of SSc. PubMed, Int J rheumatologist Dis, 10/11/2017. (Also see Prognosis and Mortality) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  6. The role of microRNA-5196 in the pathogenesis of systemic sclerosis (SSc). These results suggest that microRNA-5196 can be used as a potential biomarker characterising SSc. PubMed, Eur J Clin Invest, 06/21/2017. (Also see Prognosis and Mortality) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  7. Early mortality in a multinational systemic sclerosis (SSc) inception cohort. Early mortality in SSc is substantial and prevalent cohorts underestimate mortality in SSc by failing to capture early deaths, particularly in men and those with diffuse disease. PubMed, Arthritis Rheumatol, 12/28/2016. (Also see Prognosis and Mortality) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  8. A Proteome derived longitudinal pharmacodynamic biomarker for diffuse systemic sclerosis skin. In this study a large array of proteins were discovered, not previously associated with SSc, that provide insights into pathogenesis and potential targets for therapeutic intervention. PubMed, J Invest Dermatol, 09/14/2016. (Also see Prognosis and Mortality) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  9. Disease activity indices (DAI) in systemic sclerosis: a systematic literature review. Future studies are needed to fully validate the European Scleroderma Study Group activity index and the Combined Response Index for Systemic Sclerosis. PubMed, Clin Exp Rheumatol, 07/06/2016. (Also see Prognosis and Mortality) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  10. Increased risk of digital vascular events in scleroderma patients who have both anti–centromere (CENP) and anti–nterferon–inducible protein 16 (IF–16) antibodies. This study provides further evidence that anti–CENP and anti–IFI–16 antibodies are disease biomarkers that may be used for risk stratification of vascular events in scleroderma. PubMed, Arthritis Care Res (Hoboken), 07/07/2016. (Also see Antibodies in Systemic Scleroderma and Prognosis and Mortality) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  11. Biomarkers in systemic sclerosis (SSc): Their potential to predict clinical courses. Biomarkers that can predict clinical features, disease progress, therapeutic response and prognosis are heterogeneous among patients with systemic sclerosis. Wiley Online Library, 01/04/2016. (Also see Prognosis and Mortality) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  12. Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course. This review discusses risk factors and markers that predict the disease course and the occurrence of disease manifestations, with an emphasis on major organ involvement. PubMed, Expert Rev Clin Immunol, 2015 Dec 2:1–21. (Also see Systemic Sclerosis: Prognosis and Mortality) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×
×
  • Create New...